Odaily News Nasdaq-listed Sonnet BioTherapeutics announced that it will merge with Rorschach I LLC to form Hyperliquid Strategies and launch a crypto treasury strategy. The new entity will be renamed Hyperliquid Strategies and is expected to hold 12.6 million HYPE tokens and $305 million in cash, with a total valuation of approximately $888 million.
Rorschach I LLC was jointly established by Atlas Merchant Capital and Paradigm Operations and other sponsors. After the merger is completed, Hyperliquid Strategies will continue to be listed on Nasdaq and become a publicly traded company focused on crypto asset management, and the stock code will also be changed.
The transaction was supported by institutions such as Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital and 683 Capital. (The Block)